Federman & Sherwood Announces Filing of Securities

OKLAHOMA CITY, OK--(Marketwired - Feb 7, 2017) - On February 3, 2017, a class action lawsuit was filed in the United States District Court for the Southern District of New York against Stemline Therapeutics, Inc. ( NASDAQ : STML ). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is January 19, 2017 through February 1, 2017.

If you wish to discuss this action, obtain further information and participate in this or any other securities litigation, or should you have any questions or concerns regarding this notice or preservation of your rights, please contact: Robin Hester, FEDERMAN & SHERWOOD, 10205 North Pennsylvania Avenue, Oklahoma City, OK 73120, Email to: rkh@federmanlaw.com Or, visit the firm's website at www.federmanlaw.com

Plaintiff seeks to recover damages on behalf of all Stemline Therapeutics, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Tuesday, April 4, 2017 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.